What is the main target of eractuzumab?

Elranatamab is a bispecific antibody designed to treat hematologic malignancies such as multiple myeloma (MM). The target of this drug is very unique. It can simultaneously recognize and bind to two target molecules - B cell maturation antigen (BCMA) on the surface of myeloma cells and CD3 molecule on the surface of T cells.

BCMA is a protein highly expressed on the surface of multiple myeloma cells, making it an important target for the treatment of myeloma. By binding to BCMA, ernatumumab is able to directly recognize and bind to myeloma cells, making them targets for T cells. At the same time, CD3 is an important molecule on the surface of T cells. By binding to CD3, enatumumab can recruit T cells to the vicinity of myeloma cells. Through this dual action, enantuzumab activates T cells and directly kills myeloma cells through the T cell immune response.

The advantage of this bispecific effect is that it not only increases the aggressiveness of T cells against tumors, but also effectively enhances the anti-tumor ability of the immune system. Compared with traditional single-targeted drugs, Eractuzumab's dual-target design can kill cancer cells more accurately and cause less damage to surrounding healthy cells. Therefore, it has demonstrated significant efficacy in difficult-to-treat diseases such as multiple myeloma.

In general, the main targets of ernatumumab areBCMA and CD3. Through the combination and action of these two targets, it activates the immune system and enhances the anti-tumor ability of T cells, thereby effectively killing myeloma cells. This innovative treatment mechanism provides a new treatment idea for multiple myeloma patients and opens a new door for the development of immunotherapy drugs.

Reference materials:https://www.drugs.com/mtm/elranatamab.html